Biopharma Daily Stock Updates - 03/10/21

$XBI $141.48 +0.5% 📈

Covid Updates

$MRNA -1% First patients dosed in phase 2 study evaluating COVID-19 booster vaccine candidate. source


Pipeline Updates

$BLUE +8% Updated findings that LentiGlobin unlikely the cause of AML in clinical study. They are initiating the process to discuss with regulators to resume clinical study. source


$MNOV +54% Announced partnership with BARDA to develop MN-166 as a countermeasure to chlorine gas-induced lung injury. source


$ACET +1% Initiated phase 1 trial of ADI-001 in NHL, data expected by end of year 2021. source


$BHVN -6% Nurtec ODT approved in Israel. source


$APLS +6% Phase 2 data of Peg in GA posted in two journals, the American Journal of Ophthalmology and Ophthalmology. source


$AVEO +89% Approval of FOTIVDA (tivo) for the treatment of adult patients with R/R advanced renal cell carcinoma. Commercial launch planned by end of March 2021. source


$KDMN +1% PDUFA target date for belumosudil for chronic graft-versus-host disease extended to 8/31/21. source

0 comments